Apellis Pharmaceuticals (NASDAQ:APLS) had its price target cut by equities researchers at Citigroup from $56.00 to $54.00 in a research report issued to clients and investors on Tuesday, BenzingaRatingsTable reports. The firm currently has a "buy" rating on the stock. Citigroup's price target points to a potential upside of 75.50% from the company's previous close.
Other equities analysts have also recently issued research reports about the stock. Zacks Investment Research raised shares of Apellis Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Tuesday, March 10th. JPMorgan Chase & Co. lifted their target price on Apellis Pharmaceuticals from $54.00 to $56.00 and gave the stock an "overweight" rating in a research report on Monday, June 8th. BTIG Research initiated coverage on Apellis Pharmaceuticals in a research note on Tuesday, June 16th. They set a "neutral" rating on the stock. Oppenheimer reaffirmed a "buy" rating and set a $62.00 target price on shares of Apellis Pharmaceuticals in a research note on Friday, June 12th. Finally, Raymond James started coverage on shares of Apellis Pharmaceuticals in a research note on Tuesday, March 31st. They set a "strong-buy" rating and a $86.00 price objective on the stock. Seven research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. Apellis Pharmaceuticals currently has a consensus rating of "Buy" and an average price target of $51.00.
Shares of Apellis Pharmaceuticals stock opened at $30.77 on Tuesday. Apellis Pharmaceuticals has a 52-week low of $16.85 and a 52-week high of $45.04. The company's 50-day simple moving average is $32.10 and its 200-day simple moving average is $33.23. The firm has a market cap of $2.27 billion, a price-to-earnings ratio of -4.90 and a beta of 1.27. The company has a quick ratio of 13.25, a current ratio of 13.25 and a debt-to-equity ratio of 0.60.
Apellis Pharmaceuticals (NASDAQ:APLS) last issued its earnings results on Wednesday, April 29th. The company reported ($2.29) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($1.38) by ($0.91). Equities research analysts anticipate that Apellis Pharmaceuticals will post -6.27 EPS for the current year.
In other news, Director Alec Machiels sold 2,500 shares of the company's stock in a transaction on Monday, June 15th. The stock was sold at an average price of $30.21, for a total transaction of $75,525.00. Also, CEO Cedric Francois sold 5,000 shares of the stock in a transaction on Monday, June 15th. The shares were sold at an average price of $30.21, for a total value of $151,050.00. 9.50% of the stock is currently owned by corporate insiders.
Hedge funds have recently added to or reduced their stakes in the company. Advisor Group Holdings Inc. acquired a new position in Apellis Pharmaceuticals in the 1st quarter worth approximately $68,000. Ladenburg Thalmann Financial Services Inc. boosted its position in shares of Apellis Pharmaceuticals by 15.9% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 2,556 shares of the company's stock worth $79,000 after buying an additional 350 shares during the period. Verus Capital Partners LLC acquired a new stake in shares of Apellis Pharmaceuticals in the fourth quarter worth $81,000. Great West Life Assurance Co. Can acquired a new position in Apellis Pharmaceuticals during the fourth quarter valued at $83,000. Finally, IMA Wealth Inc. purchased a new stake in Apellis Pharmaceuticals in the 1st quarter worth about $107,000. Institutional investors and hedge funds own 72.64% of the company's stock.
About Apellis Pharmaceuticals
Apellis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is APL-2 that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria diseases; and in Phase II clinical trials for the treatment of cold agglutinin and warm antibody autoimmune hemolytic anemia diseases, as well as in Phase II clinical trials to treat four types of glomerular diseases, such as C3 glomerulopathy, IgA nephropathy, primary membranous nephropathy, and lupus nephritis.
See Also: What Is An Exchange-Traded Fund (ETF)?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
6 Stocks That Will Benefit From a Dovish Federal Reserve
The quaint correction that was labeled the “tech wreck” of 2018 seems like a distant memory to investors. What also seems like a distant memory is any thought of the Federal Reserve raising interest rates.
At the end of 2018, the Federal Reserve had raised its benchmark federal funds rate. With the trade dispute with China dragging on, there was increasing pressure on the Fed to lower interest rates. When interest rates are lower, stocks will generally rise as investors have no other option for growth.
In July 2019, the doves got their wish. But in a move that now seems to be a “what did they know move”, the Fed dropped rates again in October. The market soared to record highs in January and early February. Since mid-February however, the market has fallen dramatically, and the Fed juiced the market one more time by cutting rates down to levels not seen since the financial crisis.
None of us know for sure when the U.S. economy will be opened up. And while stocks are still a good investment, not every stock is a smart investment at this time. But some stocks perform well when interest rates are falling and that’s why we’ve prepared this presentation.
These six stocks stand to benefit from both low-interest rates and the unique economic conditions being brought on by the Covid-19 pandemic.
View the "6 Stocks That Will Benefit From a Dovish Federal Reserve".